Evolus, Inc. (EOLS)
7.76
-0.81
(-9.45%)
USD |
NASDAQ |
Sep 10, 14:17
Evolus Total Assets (Quarterly) : 248.02M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 248.02M |
| March 31, 2026 | 220.65M |
| December 31, 2025 | 225.87M |
| September 30, 2025 | 219.00M |
| June 30, 2025 | 228.80M |
| March 31, 2025 | 213.36M |
| December 31, 2024 | 232.57M |
| September 30, 2024 | 229.61M |
| June 30, 2024 | 233.77M |
| March 31, 2024 | 226.18M |
| December 31, 2023 | 189.00M |
| September 30, 2023 | 167.97M |
| June 30, 2023 | 168.98M |
| March 31, 2023 | 160.24M |
| December 31, 2022 | 177.98M |
| September 30, 2022 | 192.72M |
| June 30, 2022 | 210.92M |
| March 31, 2022 | 220.66M |
| December 31, 2021 | 257.48M |
| September 30, 2021 | 215.22M |
| Date | Value |
|---|---|
| June 30, 2021 | 239.86M |
| March 31, 2021 | 157.20M |
| December 31, 2020 | 209.07M |
| September 30, 2020 | 215.78M |
| June 30, 2020 | 194.54M |
| March 31, 2020 | 214.15M |
| December 31, 2019 | 240.44M |
| September 30, 2019 | 182.67M |
| June 30, 2019 | 202.78M |
| March 31, 2019 | 220.93M |
| December 31, 2018 | 171.84M |
| September 30, 2018 | 183.38M |
| June 30, 2018 | 121.93M |
| March 31, 2018 | 127.40M |
| December 31, 2017 | 152.23M |
| September 30, 2017 | 150.97M |
| June 30, 2017 | 146.14M |
| March 31, 2017 | |
| December 31, 2016 | 77.50M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 1.494B |
| Corcept Therapeutics, Inc. | 888.70M |
| Veru, Inc. | 37.03M |
| Johnson & Johnson | 201.06B |
| Eli Lilly & Co. | 142.28B |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 278.93M |
| Shareholders Equity (Quarterly) | -30.90M |
| Debt to Equity Ratio | -5.333 |
| Current Ratio | 1.697 |
| Net Debt Paydown Yield | -1.51% |